High response rate to crizotinib in advanced, chemoresistant ALK+ lymphoma patients.

@article{Pogliani2011HighRR,
  title={High response rate to crizotinib in advanced, chemoresistant ALK+ lymphoma patients.},
  author={Enrico Maria Pogliani and I Dilda and Federica Villa and Francesca Farina and Giovanni Giudici and Luca Guerra and Alessandro Di Lelio and Lorenza Borin and Ivana Casaroli and Luisa Verga and Carlo B Gambacorti-Passerini},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2011},
  volume={29 15_suppl},
  pages={e18507}
}
e18507 Background: The Anaplastic Lymphoma Kinase (ALK) gene is fused to several partner genes (mainly NPM) in the majority of Anaplastic Large Cell lymphoma (ALCL) patients (pts). Deregulated ALK tyrosine kinase activity represents the oncogenic driver in this disease, through the phosphorylation of proteins involved in cellular proliferation, apoptosis and differentiation. Although ALK+ ALCL pts are responsive to cytotoxic drugs, relapses occur and bear a dismal prognosis. Crizotinib is an… CONTINUE READING
8 Extracted Citations
0 Extracted References
Similar Papers

Citing Papers

Publications influenced by this paper.
Showing 1-8 of 8 extracted citations

Similar Papers

Loading similar papers…